The Fenofibrate and Microvascular Events in Type 1 Diabetic Retinopathy (FAME-1-EYE) Study
This clinical trial is investigating whether fenofibrate, a drug used to lower cholesterol, can slow or reverse eye damage in adults with type 1 diabetes. Fenofibrate has been shown to slow eye damage in type 2 diabetes, and researchers are now investigating whether the same effect will be seen in T1D.
This study has been approved by the Northern Sydney Local Health District Human Research Ethics Committee.
ANZCTR listing: ACTRN12611000249954